Enosi

Enosi

Life Sciences

Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. We invite you to join us in our efforts to develop these important, next-generation treatments. The company was founded by two world-renowned scientists.  Professor Sir Marc Feldmann (Kennedy Institute, Oxford University) discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases.  Dr. H. Michael Shepard extensively researched humanized antibodies and crea...

Security Type
Common Stock
Industry
Medical
Min Investment
$500
Location
Eugene, OR
Offering Date
July 20, 2021
Expected Close Date
July 19, 2022
Security Price
$10

Management

Dr. Jim Woody, Founder
Over 25 years of pharmaceutical research and management expertise. Current Chairman of Oncomed Pharmaceuticals, previously a founder and CEO; General Partner at Latterell Venture Partners, a venture capital group focusing on early-stage healthcare companies. Background includes significant health and management roles including President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor. When at Centocor, Jim was part of the team that developed Remicade, used to treat arthritis ; now, one of the best-selling drugs in the world.

Mr. Jeff Huitt, CFO
Jeff has more than 20 years' experience driving the financial function at start-ups and public companies. Experience includes Orion Consulting, where Jeff spent the last nine years as Principal and Consultant providing financial operations and funding support for start-up companies. Prior to Orion Consulting, Huitt acted as CFO at XsunX, Inc., Parking Stripes Advertising, Diamondback Tactical, iSherpa Capital and AirCover Network Solutions. He holds an MBA in Management from the University of Denver and is a Certified Public Accountant (CPA) in Colorado.

Dr. Michael Shepard, CEO & Co-FounderFirst FDA-approved monoclonal antibody therapy targeting breast cancer and other solid tumors...Herceptin. Herceptin/trastuzumab was a breakthrough for breast cancer therapy and a biomarker-driven drug discovery. For this work, Shepard earned the Warren Alpert Award from Harvard Medical School and the Lasker-DeBakey Clinical Medical Research Award. Shepard has participated in other successful ventures, including Canji, Inc., NewBiotics, Inc., Receptor Biologics, Halozyme Therapeutics and ENOSI.

Sir Marc Feldmann, Co-Founder & Director
Discovered (with Ravinder Maini) anti-TNF therapy as an effective treatment for rheumatoid arthritis (RA) and other autoimmune diseases. Dr. Feldmann is an internationally acknowledged thought leader on the subjects of autoimmune disease and inflammation, including evaluation of new drug candidates and clinical trial design. For his work, he has been recognized by many prizes, including the Lasker. Prize for Clinical Research. He is a member of the National Academy of Sciences (USA). The class of drugs discovered by Dr. Feldmann has become the biggest all-time income generator for Pharma, with~$40B USD in 2019. Feldmann has turned to entrepreneurship in order to facilitate his hopes of generating novel therapeutics. To do this he has started several companies, one of which, 180 Life Sciences, has just been listed on NASDAQ. Dr. Feldmann is the principal backer of Enosi Life Sciences.

Research Reports

No reports have been submitted

Become a Reporter

Security Description

Common stock is a security that represents ownership in a corporation.

Key Deal Facts

Dr. Feldmann: Best known for inventing TNF Blockers (~$40B/year industry)
Dr. Shepard: Best known for the trastuzumab/Herceptin franchise of Genentech/Roche (~$10B/year).
Both are recipients of the Albert and Mary Lasker Award for Clinical Research
These industry-leading experts will combine their talents, networks and experience to address the growing global health challenges of autoimmune diseases, cancer and acute inflammatory conditions.
The total autoimmune disease and TNF pathway drugs market is growing rapidly accelerating at a CAGR of nearly 10%

0 Comments